The Yelloach® Neuro Balloon Dilatation Catheter, independently developed by Kossel Medtech, has been approved for market release by the National Medical Products Administration (NMPA).
Intracranial atherosclerotic stenosis (ICAS) is a common cause of ischemic stroke, with significant racial disparities in incidence. It is more prevalent among Asian, Black, and Hispanic populations, contributing to an increasing global stroke burden.
In China, the mortality and disability rates of ischemic stroke caused by intracranial atherosclerosis remain high. Current treatment methods include medical therapy, surgical treatment, and endovascular intervention, with endovascular intervention offering the advantages of good efficacy, minimal postoperative trauma, and quick recovery.
The Yelloach® Neuro Balloon Dilatation Catheter is suitable for interventional treatment of non-acute symptomatic intracranial atherosclerotic stenosis patients. By dilating the balloon, it restores blood flow, improving perfusion in intracranial arteries.
The successful approval of the Yelloach® Neuro Balloon Dilatation Catheter marks a breakthrough for Kossel Medtech in the field of neuro intervention. It enriches Kossel’s diverse product portfolio in vascular intervention and provides more options for clinicians and patients.